Axonics, Inc.

Equities

AXNX

US05465P1012

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 10:23:10 2024-04-19 am EDT			5-day change	1st Jan Change
66.99 ^USD	-0.09%		-0.72%	+7.85%

Apr. 04	Boston Scientific, Axonics Receive FTC Second Request on Merger Deal	MT
Apr. 04	Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information	DJ

Axonics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 06, 2021 at 02:09 pm EDT

Axonics, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was USD 34.373 million compared to USD 26.296 million a year ago. Operating loss was USD 21.616 million compared to USD 14.705 million a year ago. Net loss was USD 22.503 million compared to USD 14.616 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.43 a year ago.

Latest news about Axonics, Inc.

Boston Scientific, Axonics Receive FTC Second Request on Merger Deal	Apr. 04	MT
Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information	Apr. 04	DJ
FTC seeks additional information for Boston Scientific's $3.7 bln Axonics deal	Apr. 04	RE
Axonics Wins Shareholder Approval of Merger With Boston Scientific	Mar. 22	MT
Axonics to File for Review After Patent Board Invalidates Claims in Medtronic Case	Mar. 21	MT
Medtronic to Ask Court to Resume Patent Infringement Case Against Axonics After Favorable Patent Office Ruling	Mar. 21	MT
Axonics to Sell Rechargeable Sacral Neuromodulation System in Europe Starting April	Mar. 14	MT
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Axonics Q4 Earnings, Revenue Rise -- Shares Edge Higher After Hours	Feb. 28	MT
Axonics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (AXNX) AXONICS Posts Q4 Revenue $109.7M	Feb. 28	MT
Boston Scientific Prices $2.17 Billion Euro-Denominated Notes Offering	Feb. 23	MT
Axonics Insider Sold Shares Worth $2,381,662, According to a Recent SEC Filing	Feb. 02	MT
Axonics Insider Sold Shares Worth $1,125,432, According to a Recent SEC Filing	Feb. 02	MT
North American Morning Briefing : TSMC Results -2-	Jan. 18	DJ
Needham Downgrades Axonics to Hold From Buy	Jan. 17	MT
North American Morning Briefing : Central Bankers -2-	Jan. 17	DJ
North American Morning Briefing : Stock Futures -2-	Jan. 16	DJ
Truist Securities Downgrades Axonics to Hold From Buy, Adjusts Price Target to $71 From $73	Jan. 12	MT
CL King Downgrades Axonics to Neutral From Buy	Jan. 12	MT
Leerink Partners Downgrades Axonics to Market Perform From Outperform, Sets Price Target at $71	Jan. 12	MT
Piper Sandler Downgrades Axonics to Neutral From Overweight, Cuts Price Target to $71 From $75	Jan. 12	MT
Axonics Insider Sold Shares Worth $1,103,961, According to a Recent SEC Filing	Jan. 11	MT
North American Morning Briefing : Focus Fixed on -2-	Jan. 11	DJ
Wells Fargo Downgrades Axonics to Equalweight From Overweight, Raises Price Target to $71 From $68	Jan. 10	MT

Chart Axonics, Inc.

Duration

Period

More charts

Company Profile

Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Axonics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

67.05 USD

Average target price

71.8 USD

Spread / Average Target

+7.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
AXONICS, INC.	+7.85%	3.42B
STRYKER CORPORATION	+9.97%	125B
SMITH & NEPHEW PLC	-10.67%	10.51B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.13%	8.65B
GLAUKOS CORPORATION	+21.11%	4.77B
ENOVIS CORPORATION	-0.46%	3.03B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-16.08%	1.97B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-12.31%	1.95B
DOUBLE MEDICAL TECHNOLOGY INC.	-30.20%	1.62B
MEDARTIS HOLDING AG	-3.57%	1.21B

Medical Devices & Implants